The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England
Biswas PN, Wilton LV, Shakir SA.
Drug Safety Research Unit, Bursledon Hall,
Southampton, London, UK.
J Psychopharmacol. 2003 Mar;17(1):121-6.


Mirtazpine is the first noradrenaline and serotonin specific antidepressant. We monitored the safety of mirtazapine as reported in primary practice in England.The exposure data were provided by monitoring the dispensed prescriptions issued between September 1997 and February 1999. Questionnaires sent to GPs provided outcome data. Drowsiness/sedation and malaise/lassitude were the most frequent ADRs (116, 71 respectively) and had the highest incidence density (per 1000 patient-months) in the first month of treatment (58.1, 27.8 respectively). Agitation (73), aggression (70), rash (20), hallucinations (13) and abnormal dreams (31 were unlabelled AES while abnormal liver function tests (12), syncope (8), abnormal behaviour (4) and visual disturbance (3) were labelled AES possibly due to mirtazapine use. Serious suspected ADRs reported were facial oedema (5), allergy (3), bone marrow toxicity (2) and myelodysplasia (1).
Mirtazapine v SSRIs
Mirtazapine and sleep
Mirtazapine : overview
Mirtazapine v paroxetine
Mirtazapine v imipramine
Mirtazapine v venlafaxine
Mirtazapine and depression
Antidepressant mechanisms
Mirtazapine and the receptors
Mirtazapine and sexual behaviour
Mirtazapine-induced dysphoric mania
Mirtazapine (Remeron) during pregnancy
Mirtazapine (Remeron): pharmacokinetics
Mirtazapine as an antidepressant: safety and efficacy
Mirtazapine (Remeron)-induced spontaneous orgasms

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family